CTOs on the Move

American Board of Nuclear Medicine

www.abnm.org

 
American Board of Nuclear Medicine is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.abnm.org
  • 4555 Forest Park Ave
    Saint Louis, MO USA 63108
  • Phone: 314.367.2225

Executives

Name Title Contact Details

Similar Companies

Proteus Biomedical

Proteus Biomedical is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Corthera

Corthera is a San Carlos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nuvalent

Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.

Rho

Welcome to a different kind of CRO. Bringing your product to market takes something different. At Rho, we`re experienced, creative problem-solvers who provide outstanding clinical research fueled by our unique team approach. Our dedication to collaboration makes your clinical trials and programs run smarter and more efficiently.

Peptilogics

Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics` lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.